Drug vignettes: Azithromycin
Description of the drug, including regulatory status: Azithromycin is a macrolide antibacterial drug, derived from erythromycin, licensed in the USA and in the UK, and used to treat bacterial infections. It has been used in combination with hydroxychloroquine in the treatment of COVID-19. However, t...
Autores principales: | Ferner, Robin E., Aronson, Jeffrey K. |
---|---|
Formato: | Published Article |
Publicado: |
2020-05-13
|
Materias: | |
Acceso en línea: | https://www.cebm.net/covid-19/drug-vignettes-azithromycin/ https://hdl.handle.net/20.500.12663/1576 |
Ejemplares similares
-
Azithromycine : les effets sur le traitement de COVID-19 sont incertains
Publicado: (2020-07-16) -
Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients
por: Carlucci, Philip et al.
Publicado: (2020-05-08) -
QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin
por: Chorin, Ehud et al.
Publicado: (2020-05-01) -
Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID‐19 Clinical Trials
por: Hughes, Jim H. et al.
Publicado: (2020-06-08) -
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection
por: Saleh, Moussa et al.
Publicado: (2020-04-29)